 Check-Cap Ltd NASDAQ: CHEK stock is moving higher on heavy volume in the premarket session after the FDA approved its Investigational Device Exemption IDE application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. C-Scan is the companys capsule-based screening technology to detect polyps before they may transform into colorectal cancer CRC to enable early intervention and cancer prevention. 